Farletuzumab ecteribulin and MORAb-109, folate receptor alpha and mesothelin targeting antibody-drug conjugates, show activity in poor prognosis gynaecological cancer models.

• Tác giả: Holly E Barker, Keiji Furuuchi, Gwo-Yaw Ho, Ratana Lim, Chloe Neagle, Ksenija Nesic, Marc Radke, Gayanie Ratnayake, Katherine Rybinski, Clare L Scott, Elizabeth M Swisher, Cassandra J Vandenberg, Matthew J Wakefield
• Ngôn ngữ: eng
• Thông tin xuất bản: United States : Clinical and translational medicine , 2025
• Bộ sưu tập: NCBI
• ID: 703951